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S_q In this single-centre study of 881 patients, S-phase fraction (SPF) was shown to be a sgnifiant
prognostic marker in terms of ovrll suvival (OS), rdapse-free survival (RFS) and survival after rlapse
(SAR). Further, SPF had dent progostic siificance when considring a range of other
cLinicopathological vaiabls, namely tumour grade and stage, nodal status, patient age, tumour size, men-
strual status and treatment details. For OS and RFS, SPF was the seond strongest prdictor of the clnical
course of the dea after nodal status, and for SAR it was the strongest prognstic marker. SPF corrlated
positively with histoll grade but was the strongr tpritor of survivaL The distribution of SPF values
was markedly different for the two pdy dasss of tumour, with DNA anepkoid tumours having a
signifiantly higher average SPF. However, SPF retained its indpedt prognosic abiity when DNA diplod
and aneuploid tumours wre analysed atly, DNA ploidy itself also proved to be an in nt
prognoic marker but the survival diffe e between the two ploidy dasses was much less than that soen for
different levels of SPF. Tumours with several DNA aneuploid populations (multiplod tumours) tended to
have a worse prognosi than other aneuploid tumours but this tre did not reach statistical siificance. In
this and othr studies from this centre, SPF has proved to be a robust prdictor of cinial outcome in
carcinonma of the breast.
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Measures of prolferative activity in breast carcinoma have
been shown to be of prognostic value in a large number of
published studis. The techniques used to assess proliferative
activity have included mitotic index (Eelinen et al., 1992),
I3Hlthynidine labelling index (Sivestrini et al., 1993), a var-
iety of immunohistochemical methods involving antibodies
such as Ki-67 (Bouzubar et al., 1989) and DNA flow
cytometry.
Although there are numerous papers on flow cytometry in
breast cancer, many of these involve fewer than 200 patients
(for reviews see Merkel and McGuire, 1990; Hedley et al.,
1993). Large single-centre data sets, involving 500 patients or
more, with long-term follow-up and information on other
prognostic factors, and in paricular tumour grade, have
rarely been reported. Such large data sets are clarly required
if the prognostic value of SPF/ploidy is to be ckarly under-
stood, quantified and compared with other known prognostic
factors. We have therefore combied the information from
several previous smaller data sets from this hospital for the
purpose of this report.
The reviews of flow cytometry and the vast majority of
published studies in which S-phase fraction (SPF) has been
measured support the view that this proliferation-related
parameter is a strong prognostic indicator in mammary car-
cinoma. The evience for DNA ploidy as a prognostic
marker, particularly one independent of other clinicopatho-
logical variables, is less convinmcng.
In this report we have brought together all the data from
several alr studies from Guy's Hospital which have
examined the potential usefulness of ploidy and SPF
measurenmets m different clinical situations. These studies
inclue an unselcted group of patiets with operable breast
cancer (O'Reilly, 1990a), a group of patients with node-
negative diseas (O'Reilly, 1990b) and a group of node-
positive patients treated in an adjuvant chemotherapy study
compring CMF (cydophosphamide, methotrexate, 5-fuorou-
racil) with controls (O'Reilly, 1990c). Further tumour
samples were studied for comparison of flow cytometric
parameters with other tumour characteristics such as histo-
logical grade (Masters et al., 1987) and c-erb-B-2 expression
(Banes et al., 1992) or for analysis of the effects of different
fixation methods on flow cytometric analyses (Gilkett et al.,
1990). These earlier studies demonstrated strong correlations
between SPF and survival but failed to demonstrate a signi-
ficant relationship between DNA ploidy and survival. The
modest size of these earlier studies (150-200 cases) did not
allow us to investigate factors such as the rekvance of SPF
within DNA diploid tumours or the prognostic s i of
DNA multiploidy. This larger cohort also facilitates examina-
tion of the relationship between tumour grade and SPF.
A further stimulus to publish our data came from two
recent reports which failed to find a prognostic role for SPF
in breast cancer (Stanton et al., 1992; Silvestini et al., 1993).
In the present tdy patients have been inuded only if data
were available on all the flow cytometric and clinicopatho-
logical parametrs included in the analysis. With complete
data on 881 patients we have investigated the relationship of
flow cytonmtric parameters to overall survival (OS), relapse-
free survival (RFS), survival after relapse (SAR) and the
clinicopathological variables listed below.
IaW ams --tdas
Patients
Selection of casesfor SPF/ploidy analyses All the patients in
this study presented at the ICRF Breast Unit at Guy's
Hospital between 1975 and 1991. During this period a total
of 3,836 new patients presented at Guy's Hospital with breast
cancer. Samples from 1,004 of these patients were sent for
flow cytometry and acceptable DNA profiles were obtained
from 881 (88%) of these cases. The 881 cases consisted of
802 patients for whom both DNA ploidy and SPF were
available. The remnaining 79 cases were multiploid tumours
for which it was not possibk to evaluate SPF. Data were
available on the following parameters in addition to SPF and
DNA ploidy: tumour grade and stage, clinical tumour size,
nodal status, patient age, menrual status, treatment and
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outcome. The mean age of the patients was 55.9 (range
21-94) years. The study group included a larger number of
patients with ten or more axiflary lymph nodes and a smaller
number of patients presenting with locally advanced/
metastatic disease than is observed for al patients treated at
this centre (Table I). This was due to the selection ofmaterial
for the separate smaller studies (see Introduction). However,
the overall outcome for the 881 patients studied was very
similar to that of the total patient population (Figure 1).
Adjuvant therapy In general, adjuvant therapy was given in
the context of a series of randomised controLld trials and
was given almost exclusively to node-positive patients until
1989. These studies included comparisons of meiphalan
(Rubens et al., 1983), CMF (Richards et al., 1990) and
tamoxifen (Singh et al., 1988) with no adjuvant therapy.
From 1985 to 1989 premenopausal patients with node-
positive tumours received either CMF or ovarian ablation
(Scottish Cancer Trials Breast Group and ICRF Breast Unit,
1993), while post-menopausal patients received tamoxifen
with or without prednisolone (Fentiman et al., 1994). From
1989 onwards premenopausal patients with node-positive
tumours (Marty et al., 1994) and those with grade m node-
negative tumours received either CMF or FEC (fluorouracil,
epirubicin, cyclophosphamide). Tamoxifen was ro n
for other patients with node-negative disease (pre- or post-
menopausal) unless the tumour size was less than 1 cm.
flow cytometry
Sampl preparation Two 50-pm sections were obtained from
routinely fixed, paraffin-embedded tissue blocks for each
case. The blocks wer shown by microscopic examination to
contain a high proportion of tumour tissue. One 50-pm
section was processed for flow cytometry and the other sec-
tion was held for use if the first section failed to yield an
interpretable DNA histogram. The method of tissue prepara-
aon and staining has been described elsewbere (Camplejohn
et al., 1989; Camplejohn, 1992). Briefly, SOpm sections were
dewaxed and taken to 50% alcohol overnight using a His-
tokinette tissue-processing machine. Tbe sections were then
rinsed in distilled water and incubated in 0.5% pepsin solu-
tion at pH 1.5 and 37C for 30min. Released nucli were
spun, washed and debris removed by filtration through a
35 pm nylon gauze filter. Nuclei were stained with a DNA-
specific dye, 4',6'-diamidino-2-phenyindole-dihydrochloride
(DAPI) at a concentration of I pgml-'. We had previously
shown that results obtained with DAPI are similar to those
obtained with the more commonly used DNA fluorocbrome
propidium iodide (Camplejohn et al., 1989). Samples were
passed twice through a 21 gauge needle, to reduce clumping,
prior to running on the flow cytometer.
Flow cytometric measurement DNA content (DAPI fluore-
scence), Coulter volume and 90 light scatter were measured
on a mercury arc-lamp powered FACS analyser (Becton
Dickinson). A standard Becton Dickinson UV filter pack was
used (excitation filters conssti of SP 375/BP 360/SP 375
and emission filters were BP 490/LP 400/LP400) with peak
excitation wavelength at 360 um and bue fluorescence
(490 nm) being colleted. Approximately 10' nuclei were
scanned to construct each DNA histogram and data were
stored in list mode on a Consort 30 computer.
Estimation ofploidy and SPF Samples with a single GI peak
were classified as DNA diploid, whie those with two such
peaks were considered DNA aneuploid. The DNA index was
calulated for the aneuploid peak by refeLence to the position
of the diploid peak; in all cases the GI peak with the lowest
DNA content was considered to be DNA diploid. For more
detail on all aspects of data analysis see Camplejohn (1992).
A method of estimating SPF was chosen originally to fulfil
certain cteria, namely that the method be simple and
capable of being performed without ass to specific coi-
141
Tie I Clbl~~ and treatment (%)h
Numbr (%)-
Mean age (range) (years)
Extent ofdisea
Oprble
Locally advanie
Metastatic
Histob;y
Ductal grade I
Ductal grade II
other
Nodal status
(ofoperale patints
only
1-3 nodes +ve
4-9 nodes +ve
> 10 nodes +ve
Unknown
Tumour size
62an
2-5an
>5cm
Unknown
Menopausal status
Pre
Eadry post (I-5yars)
Late post (>5 years)
Unknown
SurgI management
(ofoperable paents
only)
BCP
Mastectomy
No surgery
56 (21-94)
742
38
22
61
298
266
177
266
236
91
92
57
241
463
84
14
306
83
400
13
245
492
5
Adjuvant treatment
(ofoperable patients
only)
None
Cheothpmy
Endocrine dtrApy
__couservatiote p.
CD c
U
0 0
U
E
C,
3 6 9 12
Time (years)
435
156
151
92
5
3
8
37
33
22
36
32
12
12
8
30
58
10
2
38
10
50
2
33
66
1
59
21
20
15 18 21
Flwe 1 Overall survival for the patents imuld in this study
compared with the same data for all patients psenting during
thepeiodofthestudy(1975-91). , SPFnotavailable (n = 2,
955); - .. -, SPF measured (n=881).
puter hardware or software. On this basis the method of
Baisch et at. (1975) was used for DNA diploid tumours and a
modification of this technique for DNA aneuploid tumours
(Camplejohn et at., 1989, Camplejohn, 1992). SPF was cal-
culated for aneupoid cells only in the case of DNA aneu-
ploid tumours. For all DNA histograms a rectangular area
4 0%^ IPognosic signficance of DNA flowcyloiney in breast cancer
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was fitted. using a hand-held calculator, to represent the
S-phase of the cell cycle. A full-width CV was calculated for
each histogram.
Statistical analysis
Survival and relapse-free survival were calculated by the
method of Kaplan and Meier (1958), with significance being
determined using the log-rank test (Peto et al., 1977).
Patients known to have died of causes unrelated to breast
cancer were censored at their time of death. Multivariate
survival analysis was performed using Cox's proportional
hazards model (Cox. 1972). Variables were treated as con-
tinuous unless otherwise stated. The univariate results given
in Table II were obtained by entering a single factor in the
Cox model. This allows calculation of univariate P-values on
continuous variables (e.g. age. tumour size) and facilitates
comparison between the univariate and multivariate results.
Relative risks were calculated from the proportional hazards
regression coefficients. The Mann-Whitney test was used to
evaluate the significance of the difference in SPF values
between aneuploid and diploid cases.
Results
Flow cvtometrv
The mean CV for the 881 cases was 5.8% (range 2.0-10.4).
A total of 306 (35%) tumours yielded DNA diploid histo-
grams; the other 575 (65%) tumours were DNA aneuploid,
with 79 of these exhibiting multiple aneuploid clones (multi-
ploid). The overall median SPF was 7.2% (range
0.4-48.6%).
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Prognosis
Multiploid tumours did not exhibit significantly worse sur-
vival than diploid/aneuploid tumours (P=0.09, univariate
analysis. P=0.26, multivariate analysis), though the trend
was in this direction. Since SPF is not available in these
cases, the remaining analyses concern the 802 diploid and
aneuploid cases.
Survival Table II shows both univariate and multivariate
survival results for the various clinical, pathological and flow
cytometric parameters included in this study. Histological
grade, SPF, menstrual status, tumour size, nodal status and
number of nodes involved, ploidy and adjuvant chemo-
therapy were all significant as indicators of prognosis. SPF
was found to have optimum predictive power for survival
when treated as a continuous variable up to a value of 10%;
increases in SPF above 10% did not signify a worse prog-
nosis (Figure 2). The number of involved lymph nodes was
the strongest predictor of OS with a relative risk of 5.0. SPF
was the next strongest predictor with a relative risk of 2.9,
followed by histological grade with a relative risk of 2.0. The
relationship between DNA ploidy status and overall survival
was of considerably less significance than SPF; this is illus-
trated graphically in Figure 3.
Relapse-free survival Table III shows univariate and mul-
tivariate relapse-free survival results. These are very similar
to the survival results, though adjuvant chemotherapy and
adjuvant tamoxifen both show much greater significance.
Survival after relapse These results are given in Table IV.
SPF is the most significant factor, with prior adjuvant
treatments possibly compromising survival following relapse,
though these effects are not significant.
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Figure 3 Overall survival as a function of DNA ploidy: multi-
ploid tumours are excluded from this plot and were subjected to
a separate analysis. , diploid (n = 306); . aneuploid
(n = 496).
Table 11 Analysis of factors predictive for better overall survival in a group of 802 cases of breast
carcinoma (excluding 79 multiploid cases)
Univariate Multivariate
Relative Relative
Variable name r P-value riskc
a P-value riska
Nodes (0 vs 1-3 vs 4-9 vs 10+) 170.2 <0.0001 5.6 141.0 <0.0001 5.0
SPF (with > 10 coded as 10) 64.5 <0.0001 3.0 26.7 <0.0001 2.9
Histological gradeb 54.0 <0.0001 2.7 21.9 <0.0001 2.0
Tumour size (62 vs >2) 34.6 <0.0001 2.2 17.7 <0.0001 1.8
Diploid vs aneuploid 9.8 0.002 1.5 11.2 0.0008 1.7
Adjuvant chemotherapy 1.0 0.31 0.9 7.0 0.008 1.5
Not early post-menopausal status 15.3 0.0001 1.9 5.6 0.017 1.5
Adjuvant tamoxifen 3.0 0.09 1.4 3.4 0.064 1.4
aForcontinuous variables (SPF) or those with more than onecategory (nodes, histology) thiscompares
the upperand lowerquartile valuesofafitted normaldistribution. bNonductal histologies coded asgrade
2.
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Table MI Analysis offactors predictive for better relapse-free survival in a group of802 cases ofbreast
carcinoma (excluding 79 multiploid cases)
Univariate Multivariate
Relative Relative
Variable name X: P-value risk' X2 P-value risk
Nodes (0 vs 1-3 vs 4-9 vs 10+) 153.6 <0.0001 4.6 142.3 <0.0001 4.4
SPF (with > 10 coded as 10) 58.1 <0.0001 2.7 25.3 <0.0001 2.5
Histological gradeb 43.7 <0.0001 2.3 21.0 <0.0001 1.9
Tumour size ( 2 vs >2) 27.6 <0.0001 1.9 13.0 0.0003 1.6
Diploid vs aneuploid 7.4 0.007 1.3 14.7 0.0001 1.8
Adjuvant chemotherapy 0.0 0.86 1.0 19.4 <0.0001 1.9
Not early post-menopausal status 14.5 0.0001 1.8 5.3 0.02 1.4
Adjuvant tamoxifen 10.2 0.001 1.7 16.9 <0.0001 1.9
aForcontinuousvariables (SPF)orthosewith more than onecategory (nodes, histology) thiscompares
the upperandlowerquartile valuesofafitted normaldistribution. bNon-ductal histologiescodedasgrade
2.
Table IV Analysis offactors predictive for better survival after relapse in a group of802 cases ofbreast
carcinoma (excluding 79 multiploid cases)
Univariate Multivariate
Relative Relative
Variable nane X P-value risk' X2 P-value risk'
Nodes (O vs 1-3 vs4-9 vs 10+) 19.4 <0.0001 1.8 10.7 0.0003 1.6
SPF (with > 10 coded as 10) 24.6 <0.0001 1.9 13.4 0.001 2.0
Histological gradeb 20.0 <0.0001 1.8 5.8 0.02 1.4
Tumour size ( <2 vs >2) 11.7 <0.0001 1.6 9.3 0.002 1.6
Diploid vs aneuploid 5.6 0.02 1.3 2.7 0.10 1.3
Adjuvant chemotherapy 4.7 0.03 0.7 2.0 0.15 0.8
Not early post-menopausal status 5.9 0.01 1.5 2.0 0.16 1.3
Adjuvant tamoxifen 1.3 0.26 0.8 1.2 0.28 0.8
aForcontinuousvariables (SPF) or thosewith more than onecategory(nodes,histology) thiscompares
the upperand lowerquartilevalues ofafitted normaldistnbution.bNon-ductalhistologiescoded asgrade
2.
Effect of adjuvant therapy Adjuvant chemotherapy was
negatively correlated with survival on univanate analysis.
This is a result of the patient selection policy, as previously
described, with adjuvant chemotherapy being given almost
exclusively to node positive premenopausal patients. The
adjuvant chemotherapy patients thus appear to fare poorly
simply because they are, in the main, node positive. The few
node-negative patients who were given adjuvant chemo-
therapy (n = 36) were more likely to be grade III, exacer-
bating this effect (these patients were not from randomised
trials, in contrast to the node-positive patients). The mul-
tivariate results allow for this selection policy and show the
expected improvement with adjuvant chemotherapy.
Aneuploid/4loid effects Despite the strong prognostic power
of SPF when applied to all 802 cases, it is clear that the
distributions of SPF values are quite different for DNA
diploid and aneuploid tumours (P<0.001) as shown in
Figure 4. Thus, it may be more appropriate to analyse
prognostic significance of SPF separately for DNA diploid
and aneuploid cases. In separate multivariate analyses SPF
was found to be an independent prognostic indicator both in
DNA diploid cases (RR = 2.7, P =0.0026) and for DNA
aneuploid tumours (RR= 2.9, P<0.0001).
Dbusion
In earlier studies, both on patients from Guy's Hospital
(O'Reilly et al., 1990a-c) and on patients from other sites
(Brooks et al., 1993), a strong association was seen between
SPF and survival (OS, RFS and SAR). This finding is also in
agreement with the bulk of published studies (Merkel and
McGuire, 1990; Hedley et al., 1993). Given the strength of
the correlation between SPF and clinical outcome, it is not
clear why occasional studies such as those by Stanton et al.
(1992) and Silvestrini et al. (1993) fail to demonstrate a
significant prognostic ability for SPF, even in a univariate
analysis. It is always possible to invoke 'technical factors' as
the cause of the discrepancy, but we are unable to suggest
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Figue 4 The distribution of SPF values plotted separately for
DNA diploid ( _, n = 315) and DNA aneuploid (, n = 498)
tumours.
what these factors might be. In agreement with the consensus
review reported by Hedley et al. (1993), we consider that we
have demonstrated a robust association between SPF and
prognosis.
Based on the various studies from this centre related to
tumour grade and SPF measurements, clinical practice in
relation to the use of adjuvant therapy has been altered,
particularly amongst node-negative patients (O'Reilly, 1990b;
O'Reilly and Richards, 1990). High-risk node-negative
patients are identified for adjuvant therapy by a combination
of tumour size and either grade III or high SPF. We are also
planning to undertake a study of intensive adjuvant
chemotherapy in patients with four or more involved lymph
nodes. Those with grade I or low SPF tumours will, however,
be excluded.
The present study demonstrates a significant relationship
between survival and DNA ploidy status following treatment
for mammary carcinoma; indeed DNA ploidy retains
Mn
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independent prognostic power in the multivanate analyss
despite its association with SPF. Earlier reports from our
group failed to demonstrate this relationship even in a
univariate analysis (O'Reilly et al., 1990a-c), though all these
studies had shown a trend for DNA aneuploidy to signify a
poorer prognosis. Further, the results of the present study
are in ine with the overview from the literature in that, while
DNA ploidy is significntly ted to cinical outcome, the
magnitude of the survival advantage of a DNA diploid
tumour over an aneuploid one is small (Camplejohn and
Macartney, 1992; Hedley et al., 1993). Thus, it appears to be
no sary to have a large number of cases to be able to
demonstrate a signiicnt association between DNA ploidy
status and clinical outcome. Since the survival advantage
predicted by DNA ploidy status is sma4, the practical utility
of this parameter appears limited.
A partcular subgroup of tumours can be identied in
terms of their ploidy status, namely those tumours which
exhibit more than one aneupkoid done, so-called DNA mul-
tiploid tumours. There were 79/881 such tumours in the
present study. Using our analysis method, no SPF values can
be calculated for these cases, and as SPF is a strong prognos-
tic indicator consideable value is lost from the flow cytomet-
ric measurements for these DNA multiploid cases. Thus we
looked particularly at the question as to whether DNA mul-
tiploidy itself was a stronger prognostic marker than simple
DNA aneuploidy and thus whether the finding of DNA
multiploidy might replace SPF as a prognostic indicator for
these cases. There was a trend for DNA multiploid tumours
to have a worse prognosis than other DNA aneuploid
tumours, but this association failed to reach a statistically
signiiant level in both the umivariate (P = 0.09) and the
multivariate (P = 0.26) analysis. Neverthless, the possible
use of DNA multiploidy as a prognostic marker might war-
rant further study.
In earler, smaller studies (O'Reilly et al., 1990a-c) it was
not possible to determine the prognostic value of SPF for
DNA diploid tumours alone owing to an inadequate number
of such tumours. However, it was clear in these earlier
investigations, as in the present one, that SPF is icantly
lower in DNA diploid tumours than in aneuploid ones (see
Figure 4). Thus it may be appropriate to consider the value
of SPF as a prognostic marker separately for the two DNA
ploidy categories. It was possible to demonstrate that SPF is
a sign nt independent predictor of survival in DNA dip-
loid as well as aneuploid tumours in the present study. This
is despite the fact that DNA diploid tumour stem lines are
inevitably con ted with non-malignant diploid cells.
With certain types of flow cytometer it may be possible to
distinguish normal DNA diploid cells from malignant diploid
cells g light scatter characterstics (MG Ormerod, per-
sonal communication). Alternatively, if fresh tissue is used
for DNA flow cytometry it may be possible to use antibodi
to cllular eins to identify tumour from nomal cells,
although this increases the labour and cost of the procedure
(Ferrero et al., 1990). Either method of removing normal
cells from the analysis of SPF for DNA diploid tumours
would be expected to improve further the prognostic power
of this parameter.
A particular point of interest to us has been the nature of
the assoation between tumour grade and SPF. As repoted
in our earler studi (O'Reilly et al., 1990a-c) and by many
others (Merkel and McGuire, 1990; Hedley et al., 1993),
there is a strong association bten these two parametr.
In our earlier, smaller stude it was not possible to demon-
strate an indepedent prognostic power for SPF when
tumour grade was included in the multivariate analysis. In
this larger cohort ofpatients, such an independent prognostic
ability for SPF could be demonstrated and the x2 value for
SPF (26.7) was higher than that for tumour grade (21.9). In
the ICRF Clinical Oncology Unit at Guy's Hospital tumour
grading is given a high priority and is performed in a his-
topathology laboratory dicted to the study of breast
lesions; under these circumstances tumour grade has always
shown a strong association with clinical outcome. In other
studies, however, tumour grade has not been a useful prog-
nostic marker (Brooks et al., 1993). In all of these studies
ther has consistently been a strong association between SPF
and clnical outcome. The relative merits of tumour grade
and SPF as prognostic markers clerly depend on the quality
of each asseent, but the present large study suggests that
SPF is at kast as good as tumour grade in predicting clinical
outcome for those tumours for which SPF is available.
It is quite often claimed that DNA flow cytometry is
unsuitable as a routine method because of the cost of the
equipment required. However, in preparing a putative budget
for performing DNA flow cytometry on all new cases of
breast cancer'in the South-East Thames Region some years
ago, we found that the cost per sample was not overly
expensive when mesurmets were performed in a single
central facility (Campkjohn, 1993). The main practical disad-
vantage of DNA flow cytometry in breast cancer would seem
to be the inability to obtain SPF data on around 25% of
patiets presentng. Some of the faires are due to the
inability to obtain good DNA histograms, and the magnitude
ofthis problem might be reduced by modifications to fixation
procedures for praffin-embedded samples (Gillett et al.,
1990) or by the use offine-needle aspiration of unfixed tissue
to obtain material for flow cytometry (Vindelov and Chris-
tensen, 1990). However, the majority of cases which fail to
yield SPF data are the result of probiems in cculating SPF
caused by factors such as DNA multiploidy, diploid and
aneuploid GI peaks being too close together or very small
aneupnoid peaks. It is possible that modern computer pro-
grams available now might improve this situation somewhat
(Hedley et al., 1993), but it seems hikely that there will always
be a sinficant minority of cases for which an SPF value
cannot be alclated.
Recent matatical models (Gregory et al., 1991) suggest
that when a factor correlates with tumour growth rate the
relaps-free surival curves should show different slopes
(steeper slopes for faster growing tumours). This can be seen
with the SPF curves shown in this study (the relapse-free
survival curves are similar to the survival curves shown in
Figure 2), confirming a correlation with the growth rate of
the tumour. Since the effect ofchemotherapy is thought to be
greatest for rapidly dividng tumours, this supports the policy
of usng SPF to select patients for adjuvant chemotherapy.
From the data in this study and the consensus revew of
the literature (Hedley et al., 1993), it is ckar that SPF is a
powerful prognostic indicator in breast cancer. In common
with the measurement of all present proliferative marers,
SPF measurement suffers from some drawbacks, for example
the inability to assess SPF in multiploid cases. However, it
wes to have potential for defining subgroups for which
approprate treatments can be seected. For example, it may
have a particular role in defining those patients with node-
negative diseas who require adjuvant systemic therapy
(Toikkanen et al., 1989; O'Reilly et a,, 199; Sigurdon et
al., 1990).
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